glp 1 agonist classification of 1R Agonists Research shows GLP-1 receptor agonist
Description
Orforglipron Orforglipron (Eli Lilly) is a novel oral GLP-1 receptor agonist that is currently in phase 3 clinical trials
Additionally, motor dysfunction in PD patients leads to reduced physical activity, further affecting energy consumption and metabolism (22)
Copyright The Author(s) 2025
Article highlights - GLP-1 receptor agonists cause gastrointestinal symptoms, but these effects do not usually cause discontinuation of therapy
Matschinsky F, Liang Y, Kesavan P, et al
